| P2093 | author name string | Beijnen JH | |
| | Schellens JH | |
| | Voest EE | |
| | Witteveen PO | |
| | Daehling A | |
| | Kuppens IE | |
| | Schot M | |
| | Schuessler VM | |
| P2860 | cites work | Chemotherapeutic neuropathy | Q33790285 |
| | Mechanism of action of antitumor drugs that interact with microtubules and tubulin | Q34188643 |
| | Past and future of the mitotic spindle as an oncology target | Q34441105 |
| | Neurotoxicity of antineoplastic agents | Q40847058 |
| | Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). | Q42550306 |
| | Motor neuropathy due to docetaxel and paclitaxel | Q42555288 |
| | Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry | Q44951077 |
| | Role of taxanes in lung-cancer chemotherapy | Q77420410 |
| | THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS | Q29308301 |
| | D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity | Q31983554 |
| | Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death | Q33539855 |
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| | phase I clinical trial | Q5452194 |
| P304 | page(s) | 227-235 | |
| P577 | publication date | 2006-12-05 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. | |
| P478 | volume | 25 | |